PRTA Stock Overview
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Prothena Corporation plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.74 |
| 52 Week High | US$79.38 |
| 52 Week Low | US$19.65 |
| Beta | 0.24 |
| 1 Month Change | 1.58% |
| 3 Month Change | -9.77% |
| 1 Year Change | -69.12% |
| 3 Year Change | 1.50% |
| 5 Year Change | 147.55% |
| Change since IPO | 229.72% |
Recent News & Updates
Recent updates
Prothena: Alzheimer's Data Update In 2024 Could Move The Needle
Feb 23Investors Don't See Light At End Of Prothena Corporation plc's (NASDAQ:PRTA) Tunnel And Push Stock Down 33%
Feb 08
Are Investors Undervaluing Prothena Corporation plc (NASDAQ:PRTA) By 32%?
Dec 20Prothena (NASDAQ:PRTA) Is In A Strong Position To Grow Its Business
Nov 24Prothena Corporation plc's (NASDAQ:PRTA) 29% Share Price Plunge Could Signal Some Risk
Oct 27Companies Like Prothena (NASDAQ:PRTA) Are In A Position To Invest In Growth
Aug 25What You Need To Know About The Prothena Corporation plc (NASDAQ:PRTA) Analyst Downgrade Today
May 10We Think Prothena (NASDAQ:PRTA) Can Easily Afford To Drive Business Growth
Apr 23Time To Worry? Analysts Just Downgraded Their Prothena Corporation plc (NASDAQ:PRTA) Outlook
Mar 01We're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn Rate
Dec 28Prothena: Paying A Premium To Cover All The Alzheimer's Bases
Sep 29Prothena GAAP EPS of -$0.88 misses by $0.31
Aug 08Bearish: Analysts Just Cut Their Prothena Corporation plc (NASDAQ:PRTA) Revenue and EPS estimates
May 08Are Prothena Corporation plc (NASDAQ:PRTA) Investors Paying Above The Intrinsic Value?
Jan 10Prothena: A Biotech Company With A Promising Pipeline
Dec 01Shareholder Returns
| PRTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.0% | 3.4% | 1.6% |
| 1Y | -69.1% | 3.8% | 25.1% |
Return vs Industry: PRTA underperformed the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: PRTA underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| PRTA volatility | |
|---|---|
| PRTA Average Weekly Movement | 7.9% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PRTA's share price has been volatile over the past 3 months.
Volatility Over Time: PRTA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 173 | Gene Kinney | www.prothena.com |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis.
Prothena Corporation plc Fundamentals Summary
| PRTA fundamental statistics | |
|---|---|
| Market cap | US$1.28b |
| Earnings (TTM) | -US$147.03m |
| Revenue (TTM) | US$91.37m |
14.0x
P/S Ratio-8.7x
P/E RatioIs PRTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PRTA income statement (TTM) | |
|---|---|
| Revenue | US$91.37m |
| Cost of Revenue | US$220.57m |
| Gross Profit | -US$129.20m |
| Other Expenses | US$17.83m |
| Earnings | -US$147.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -2.74 |
| Gross Margin | -141.40% |
| Net Profit Margin | -160.92% |
| Debt/Equity Ratio | 0% |
How did PRTA perform over the long term?
See historical performance and comparison